SCHEMBL811015

SCHEMBL811015

CC(C)(C)OC(=O)Nc1ccc(Sc2ccc(OCc3cnc(Cl)s3)cc2Nc2ncnc3nc(C(C)(C)C)ccc23)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.45
AKT2 P31751 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.40
CDK1 P06493 1/20 0.36
EGFR P00533 1/20 0.36
SRC P12931 1/20 0.36
LMNA P02545 2/20 0.34
MAPT P10636 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
POLB P06746 1/20 0.34
RAB9A P51151 1/20 0.34
ATM Q13315 1/20 0.34
SIRT2 Q8IXJ6 1/20 0.34
AURKA O14965 1/20 0.33
AURKB Q96GD4 1/20 0.33
SREBF2 Q12772 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL811255 0.87 PIM1 (0.48) PIM1AKT2L3MBTL1LMNAMAPT
SCHEMBL1455204 0.81 KDM4E (0.41) PIM1AKT2CDK1EGFRSRC
SCHEMBL1455418 0.81 PRMT1 (0.40) PIM1AKT2L3MBTL1CDK1EGFR
SCHEMBL810859 0.79 PIM1 (0.69) PIM1AKT2L3MBTL1LMNAMAPT
SCHEMBL1454599 0.78 KDR (0.41) PIM1AKT2CDK1EGFRSRC
SCHEMBL810430 0.78 L3MBTL1 (0.52) L3MBTL1LMNAMAPTMEN1KMT2A
SCHEMBL810669 0.77 PIM1 (0.56) PIM1AKT2L3MBTL1LMNAMEN1
SCHEMBL811265 0.77 L3MBTL1 (0.48) L3MBTL1LMNAMAPTMEN1KMT2A
SCHEMBL810796 0.75 PIM1 (0.48) PIM1AKT2L3MBTL1LMNAMEN1
SCHEMBL1717034 0.75 MAPK1 (0.40) PIM1AKT2CDK1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
EP-1971611-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-09-24 EP disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885L3MBTL1 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.